SAN DIEGO, Aug. 7, 2007 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (NasdaqGM:MNOV - News) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced that it will present findings from its Phase I trial of MN-029 at the 14th European Cancer Conference (ECCO 14). This conference will be held in Barcelona, Spain, September 23 to 27, 2007.
